UBS raised the firm’s price target on Medtronic (MDT) to $95 from $94 and keeps a Neutral rating on the shares. Medtronic now has the pieces in place, but execution remains the key for reaccelerating organic sales growth, the analyst tells investors in a research note.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MDT:
- Medtronic price target raised to $96 from $94 at Baird
- Medtronic price target raised to $98 from $97 at Bernstein
- Medtronic’s Strong Financial Performance and Positive Outlook Justify Buy Rating
- Medtronic price target raised to $100 from $98 at Wells Fargo
- Positive Outlook for Medtronic Amid Strategic Changes and Elliott Management Investment